Investment
Features
FeesSafety
Academy
More
Pluang+

Compare GameStop Corp. (GME) vs Medpace Holdings Inc (MEDP) Price & Performance

GameStop Corp.Trade
Medpace Holdings IncTrade

Price performance (Past 24H)

Key statistics

GameStop Corp. vs Medpace Holdings Inc — how do they compare? GameStop Corp. trades at $22.38 (market cap $9.99B), while Medpace Holdings Inc trades at $534.43 (market cap $15.11B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and Medpace Holdings Inc is trading nearer its 52-week high, GameStop Corp. nearer its low. Which is the better fit depends on your goals.

GMEMEDP
Market Cap
$9.99B$15.11B
Sector
Consumer CyclicalTechnology
52-Week High
$27.69$620.59
52-Week Low
$19.94$308.88
Enterprise Value
$5.96B$14.58B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

GameStop Corp.

GME trades at $22.43, up 1.82% today, with a bullish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $0.30 exceeding the $0.16 estimate. Revenue for 2025 was $3.82 billion, with net income of $131.3 million, marking a significant turnaround from prior losses. Recent news highlights a partnership with Uber Eats and a proposed eBay acquisition as strategic growth catalysts.

The outlook is mixed; fundamentals show improving profitability and a robust balance sheet with $4.77 billion cash, but revenue declines and competitive pressures from digital game distribution pose risks. Analyst sentiment is cautious with only 16.7% buy ratings. Key opportunities include EBITDA guidance exceeding $600 million for 2026, while execution risks around the eBay bid and industry shifts remain headwinds.

Medpace Holdings Inc

Medpace (MEDP) trades at $534.85, down 0.25% on the day, with a bullish technical signal from moving averages and RSI near oversold levels. The company shows strong profitability with a 17.19% net income margin and 77.25% ROE, though valuations are elevated with a P/E of 33.31. Recent earnings have consistently beaten estimates, and cash flow is projected to improve in 2026. News highlights focus on CRO demand shifts and a class action lawsuit from June 2026.

Outlook remains mixed; strong earnings momentum and operational efficiency support upside, but high valuation and legal overhangs pose risks. Analyst consensus is cautious with a $497 price target below current levels, suggesting limited near-term appreciation potential amid balanced investor sentiment.

Returns comparison

Trailing returns across standard periods

About GameStop Corp.

Global Market Group Ltd. operates an Internet website that connects Chinese manufacturers with international buyers. The Company's customers can post company profiles and product information in standardized formats; post product listings; and trade leads.

Read more on GME

About Medpace Holdings Inc

Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.

Read more on MEDP